利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

243 records (took 0.039 seconds)

    BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY
    4.
    发明公开
    BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY 审中-公开
    BROMODOMAIN抑制剂作为辅助治疗癌症免疫治疗

    公开(公告)号：EP3226898A1

    公开(公告)日：2017-10-11

    申请号：EP15864653.9

    申请日：2015-12-04

    Applicant: H. Lee Moffitt Cancer Center And Research Institute, Inc. ,  Dana-Farber Cancer Institute, Inc.

    Inventor： SOTOMAYOR, Eduardo M. ,  BRADNER, James ,  TAO, Jianguo

    IPC: A61K39/395 ,  A61K31/33

    CPC classification number: A61K31/5517 ,  A61K39/39 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/55511 ,  C12N5/0636 ,  C12N2501/999 ,  C12N2502/11 ,  A61K2300/00

    Abstract: Inhibition of bromodomain proteins in antigen presenting cells is shown herein to be more inflammatory, to display lower expression of the immunosuppressive molecule PDL1, and to be capable of restoring the responsiveness of tolerant T-cells. Therefore, disclosed is a method for promoting T-cell activation during cancer immunotherapy in a subject that involves administering to a subject undergoing cancer immunotherapy a composition comprising a bromodomain inhibitor. Also disclosed is a method for treating cancer in a subject, comprising co-administering to the subject a bromodomain inhibitor and an immunostimulatory agent.

    Abstract translation: 本文显示抗原呈递细胞中溴结构域蛋白的抑制更具炎症性，表现出免疫抑制分子PDL1的较低表达，并且能够恢复耐受性T细胞的响应性。 因此，公开了一种促进受试者癌症免疫疗法期间T细胞活化的方法，其涉及向正在进行癌症免疫疗法的受试者施用包含溴结构域抑制剂的组合物。 还公开了用于治疗受试者中的癌症的方法，包括向受试者共同施用溴结构域抑制剂和免疫刺激剂。

    DEVICE-BASED METHODS FOR LOCALISED DELIVERY OF CELL-FREE CARRIERS WITH STRESS-INDUCED CELLULAR FACTORS
    5.
    发明授权
    DEVICE-BASED METHODS FOR LOCALISED DELIVERY OF CELL-FREE CARRIERS WITH STRESS-INDUCED CELLULAR FACTORS 有权
    基于设备的方法用应力诱导的细胞因子局部传送无细胞载体

    公开(公告)号：EP2809333B1

    公开(公告)日：2017-08-16

    申请号：EP13701801.6

    申请日：2013-01-31

    Applicant: Technische Universität München - Klinikum Rechts der Isar

    Inventor： SCHILLING, Arndt ,  HADJIPANAYI, Ektoras ,  MACHENS, Hans-Günther

    IPC: A61K38/00 ,  A61L27/00 ,  A61K35/12

    CPC classification number: C12N5/0641 ,  A61K35/12 ,  A61K38/00 ,  A61K38/18 ,  A61K38/1825 ,  A61K38/1858 ,  A61K38/1866 ,  A61K38/1891 ,  A61K38/2053 ,  A61L15/40 ,  A61L15/44 ,  A61L17/005 ,  A61L26/0057 ,  A61L26/0066 ,  A61L27/38 ,  A61L27/3895 ,  A61L27/54 ,  A61L31/005 ,  A61L31/16 ,  A61L2300/414 ,  C12M29/04 ,  C12M35/02 ,  C12M35/04 ,  C12M35/08 ,  C12N5/0634 ,  C12N5/0644 ,  C12N2500/02 ,  C12N2502/11 ,  C12N2502/1128 ,  C12N2502/115 ,  C12N2533/40 ,  C12N2533/54 ,  C12N2533/56

    Abstract: The present invention relates to an in vitro or ex vivo method of preparing a cell-free composition, said method comprising or consisting of (a) subjecting cells to stress; and (b) collecting factors produced, preferably secreted by said cells when subjected to said stress, thereby obtaining said cell-free composition; wherein said cells are comprised in or form at least one first carrier and said collecting is effected by means of at least one second carrier which second carrier(s) is/are cell-free and concomitantly present with and spatially distinct from said first carrier; and said collecting is effected using a device comprising or consisting of (i) said first carrier(s) which first carrier(s) comprise(s) said cells or is/are suitable to hold said cells; (ii) said second carrier(s) which is cell-free; and (iii) means of subjecting said cells in said first carrier to stress; wherein first carrier(s) and second carrier(s) are positioned such that factors secreted by said cells when subjected to stress are collected in said second carrier(s), wherein means are positioned between said first and second carrier which prevent any cells and/or pathogens present in (any of) said first carrier(s) from entering into said second carrier(s).

    Abstract translation: 本发明涉及制备无细胞组合物的体外或离体方法，所述方法包括以下或由以下组成：（a）使细胞经受应激; 和（b）收集所产生的因子，优选在受到所述应激时由所述细胞分泌，由此获得所述无细胞组合物; 其中所述细胞被包含在或形成至少一个第一载体，并且所述收集借助于至少一个第二载体实现，所述第二载体是无细胞的且伴随地与所述第一载体存在并且在空间上不同; 并且所述收集使用包含以下物质或由以下物质组成的装置进行：（i）所述第一载体，所述第一载体包含所述细胞或者适合于保持所述细胞; （ii）无细胞的所述第二载体; 和（iii）使所述第一载体中的所述细胞受到应激的手段; 其中第一载体和第二载体被定位成使得由所述细胞在受到压力时分泌的因子被收集在所述第二载体中，其中所述装置位于所述第一载体和第二载体之间，防止任何细胞和 /或存在于所述第一载体（中的任何一个）中的病原体进入所述第二载体。

    The use of apoptotic cells ex vivo to generate regulatory T cells
    6.
    发明授权
    The use of apoptotic cells ex vivo to generate regulatory T cells 有权
    离体细胞凋亡剂Zellen zur Erzeugung调节剂T-Zellen

    公开(公告)号：EP2443922B1

    公开(公告)日：2017-05-03

    申请号：EP11179826

    申请日：2006-11-02

    Applicant: THERAKOS INC

    Inventor： PERITT DAVID ,  CAMPBELL KIM ,  KRUTSICK AMY

    IPC: C12N5/0783 ,  A01N1/02 ,  A01N63/00 ,  A61K31/366 ,  A61K31/59 ,  A61K35/17

    CPC classification number: C12N5/0637 ,  A61K31/366 ,  A61K31/59 ,  A61K35/17 ,  C12N5/0636 ,  C12N2500/38 ,  C12N2501/15 ,  C12N2501/23 ,  C12N2501/231 ,  C12N2501/39 ,  C12N2502/11

    Abstract: Many cell types in the body can remove apoptotic and cellular debris from tissues; however, the professional phagocyte, or antigen presenting cell ('APC'), has a high capacity to do so. The recognition of apoptotic cells ('ACs') occurs via a series of evolutionarily-conserved, AC associated molecular-pattern receptors ('ACAMPRs') on APCs that recognize and bind corresponding apoptotic-cell-associated molecular patterns ('ACAMPs'). These receptors recognize ligands such as phosphotidyl serine and oxidized lipids found on apoptotic cells. Savill et al. (2002); and Gregory et al. (2004).

    Abstract translation: 身体中的许多细胞类型可以从组织中去除凋亡和细胞碎片; 然而，专业吞噬细胞或抗原呈递细胞（“APC”）具有很高的能力。 凋亡细胞（“AC”）的识别通过一系列进化保守的AC相关分子模式受体（“ACAMPR”）在APC上发生，其识别并结合相应的凋亡细胞相关分子模式（“ACAMP”）。 这些受体识别在凋亡细胞上发现的配体如磷脂酰丝氨酸和氧化的脂质。 Savill等人 （2002年）; 和格雷戈里（Gregory）等 （2004年）。

    METHODS FOR INDUCTION OF ANTIGEN-SPECIFIC REGULATORY T CELLS
    8.
    发明公开
    METHODS FOR INDUCTION OF ANTIGEN-SPECIFIC REGULATORY T CELLS 审中-公开
    VERFAHREN ZUR INDUZIERUNG抗生素调节剂T-ZELLEN

    公开(公告)号：EP3063270A1

    公开(公告)日：2016-09-07

    申请号：EP14801949.0

    申请日：2014-10-29

    Applicant: ImCyse SA

    Inventor： SAINT-REMY, Jean-Marie ,  CARLIER, Vincent ,  VANDER ELST, Luc

    IPC: C12N5/0783

    CPC classification number: A61K35/17 ,  A61K2035/124 ,  C12N5/0637 ,  C12N5/0646 ,  C12N2502/11

    Abstract: The present invention relates to methods of obtaining antigen-specific regulatory cells in vitro or in vivo. The regulatory cells are obtainable by inducing apoptosis of antigen- presenting cells by NKT cells. In particular, NKT cells are elicited, in vitro or in vivo, by exposure to CD1d-restricted NKT cell peptide epitopes either in natural configuration or modified as to contain a thioreductase motif within flanking residues. The present invention discloses methods to elicit immature antigen-presenting cells loaded with apoptotic cells or with apoptotic bodies for suppressing or preventing diseases such as autoimmune diseases, graft rejection and allergic diseases, and medicaments related thereto. Further disclosed are the use of antigen-specific regulatory cells for suppressing or preventing diseases such as autoimmune diseases, graft rejection and allergic diseases, and medicaments related thereto. Further disclosed are populations of antigen-specific regulatory cells obtained by this method.

    Abstract translation: 本发明涉及在体外或体内获得抗原特异性调节细胞的方法。 通过NKT细胞诱导抗原呈递细胞的凋亡可获得调节细胞。 特别地，通过暴露于天然构型中的CD1d限制性NKT细胞肽表位或修饰以在侧翼残基中含有硫氧还原酶基序，在体外或体内引起NKT细胞。 本发明公开了引发具有凋亡细胞或凋亡小体的未成熟抗原呈递细胞的方法，用于抑制或预防诸如自身免疫疾病，移植排斥反应和过敏性疾病等疾病以及与之有关的药物。 进一步公开的是抗原特异性调节细胞用于抑制或预防诸如自身免疫性疾病，移植物排斥反应和过敏性疾病等疾病以及与之有关的药物。 进一步披露的是通过该方法获得的抗原特异性调节细胞的群体。

Patent Agency Ranking